Trial Profile
EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Sponsors Novartis Pharma
- 31 May 2011 New trial record